Targeting inflammatory pathways in chronic lymphocytic leukemia

Critical Reviews in Oncology/Hematology

Volumn 88, Issue 3, 2013, Pages 655-666

  Rozovski, Uri ^a   Keating, Michael J ^a   Estrov, Zeev ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Chronic lymphocytic leukemia; CLL; Experimental therapy; Inflammation

Indexed keywords

B LYMPHOCYTE RECEPTOR; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; DASATINIB; FOSTAMATINIB; GLUCOCORTICOID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IBRUTINIB; IDELALISIB; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 10; INTERLEUKIN 4; INTERLEUKIN 6; INTERLEUKIN 8; LENALIDOMIDE; NONSTEROID ANTIINFLAMMATORY AGENT; STAT3 PROTEIN; TOLL LIKE RECEPTOR; TUMOR NECROSIS FACTOR ALPHA;

ANTINEOPLASTIC ACTIVITY; ATM GENE; CANCER CHEMOTHERAPY; CANCER GROWTH; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL SURVIVAL; CHRONIC INFLAMMATION; CHRONIC LYMPHATIC LEUKEMIA; DERMATOLOGY; DRUG EFFICACY; DRUG INHIBITION; ENZYME REPRESSION; GASTROINTESTINAL TOXICITY; GENE; HUMAN; INFECTION; INFLAMMATION; MENTAL DISEASE; METABOLISM; MUSCULOSKELETAL DISEASE; MYD88 GENE; NATURAL KILLER CELL; NONHUMAN; NOTCH1 GENE; PATHOGENESIS; REVIEW; SIDE EFFECT; SIGNAL TRANSDUCTION; SOMATIC MUTATION; TUMOR FLARE;

CHRONIC LYMPHOCYTIC LEUKEMIA; CLL; EXPERIMENTAL THERAPY; INFLAMMATION;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTINEOPLASTIC AGENTS; HUMANS; IMMUNOLOGIC FACTORS; INFLAMMATION; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MUTATION; PROTEIN KINASE INHIBITORS; SIGNAL TRANSDUCTION;

EID: 84888301257     PISSN: 10408428     EISSN: 18790461     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2013.07.011     Document Type: Review

References (106)

1. Rai K.R., Keating M.J. Staging and prognosis of chronic lymphcoytie leukemia. UpToDate 2013, UpToDate, Waltham, MA. B.D. Rose (Ed.).
2. Hallek M., Cheson B.D., Catovsky D., Caligaris-Cappio F., Dighiero G., Dohner H., et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 2008, 111:5446-5456.
3. Duhrsen U., Augener W., Zwingers T., Brittinger G. Spectrum and frequency of autoimmune derangements in lymphoproliferative disorders: analysis of 637 cases and comparison with myeloproliferative diseases. British Journal of Haematology 1987, 67:235-239.
4. Weed R.I. Exaggerated Delayed Hypersensitivity to Mosquito Bites in Chronic Lymphocytic Leukemia. Blood 1965, 26:257-268.
5. Davis M.D., Perniciaro C., Dahl P.R., Randle H.W., McEvoy M.T., Leiferman K.M. Exaggerated arthropod-bite lesions in patients with chronic lymphocytic leukemia: a clinical, histopathologic, and immunopathologic study of eight patients. Journal of the American Academy of Dermatology 1998, 39:27-35.
6. Tsiodras S., Samonis G., Keating M.J., Kontoyiannis D.P. Infection and immunity in chronic lymphocytic leukemia. Mayo Clinic Proceedings 2000, 75:1039-1054.
7. Dearden C. Disease-specific complications of chronic lymphocytic leukemia. American Society of Hematology Education Program 2008, 450-456.
8. Pavlidis A.N., Kalef-Ezra J., Bourantas L.C., Lambrou A., Mavridis A. Serum tumor markers in non-Hodgkin's lymphomas and chronic lymphocytic leukemia. International Journal of Biological Markers 1993, 8:14-20.
9. Wierda W.G., O'Brien S., Wang X., Faderl S., Ferrajoli A., Do K.A., et al. Characteristics associated with important clinical end points in patients with chronic lymphocytic leukemia at initial treatment. Journal of Clinical Oncology 2009, 27:1637-1643.
10. Xie J., Yi Q. Beta2-microglobulin as a potential initiator of inflammatory responses. Trends in Immunology 2003, 24:228-229. author reply 9-30.
11. Yan X.J., Dozmorov I., Li W., Yancopoulos S., Sison C., Centola M., et al. Identification of outcome-correlated cytokine clusters in chronic lymphocytic leukemia. Blood 2011, 118:5201-5210.
12. Mahadevan D., Choi J., Cooke L., Simons B., Riley C., Klinkhammer T., et al. Gene expression and serum cytokine profiling of low stage CLL identify WNT/PCP, Flt-3L/Flt-3 and CXCL9/CXCR3 as regulators of cell proliferation, survival and migration. Human Genomics and Proteomics 2009, 2009:453634.
13. Fayad L., Keating M.J., Reuben J.M., O'Brien S., Lee B.N., Lerner S., et al. Interleukin-6 and interleukin-10 levels in chronic lymphocytic leukemia: correlation with phenotypic characteristics and outcome. Blood 2001, 97:256-263.
14. Yoon J.Y., Lafarge S., Dawe D., Lakhi S., Kumar R., Morales C., et al. Association of interleukin-6 and interleukin-8 with poor prognosis in elderly chronic lymphocytic leukemia patients. Leukemia and Lymphoma 2012.
15. Collins R.J., Verschuer L.A., Harmon B.V., Prentice R.L., Pope J.H., Kerr J.F. Spontaneous programmed death (apoptosis) of B-chronic lymphocytic leukaemia cells following their culture in vitro. British Journal of Haematology 1989, 71:343-350.
16. Badoux X., Bueso-Ramos C., Harris D., Li P., Liu Z., Burger J., et al. Cross-talk between chronic lymphocytic leukemia cells and bone marrow endothelial cells: role of signal transducer and activator of transcription 3. Human Pathology 2011, 42:1989-2000.
17. Burger J.A. Nurture versus nature: the microenvironment in chronic lymphocytic leukemia. Hematology American Society of Hematology Education Program 2011, 2011:96-103.
18. Dietrich S., Kramer O.H., Hahn E., Schafer C., Giese T., Hess M., et al. Leflunomide induces apoptosis in fludarabine-resistant and clinically refractory CLL cells. Clinical Cancer Research 2012, 18:417-431.
19. Douglas R.S., Capocasale R.J., Lamb R.J., Nowell P.C., Moore J.S. Chronic lymphocytic leukemia B cells are resistant to the apoptotic effects of transforming growth factor-beta. Blood 1997, 89:941-947.
20. Kern C., Cornuel J.F., Billard C., Tang R., Rouillard D., Stenou V., et al. Involvement of BAFF and APRIL in the resistance to apoptosis of B-CLL through an autocrine pathway. Blood 2004, 103:679-688.
21. Del Giudice I., Chiaretti S., Tavolaro S., De Propris M.S., Maggio R., Mancini F., et al. Spontaneous regression of chronic lymphocytic leukemia: clinical and biologic features of 9 cases. Blood 2009, 114:638-646.
22. Palmer S., Hanson C.A., Zent C.S., Porrata L.F., Laplant B., Geyer S.M., et al. Prognostic importance of T and NK-cells in a consecutive series of newly diagnosed patients with chronic lymphocytic leukaemia. British Journal of Haematology 2008, 141:607-614.
23. Gonzalez-Rodriguez A.P., Contesti J., Huergo-Zapico L., Lopez-Soto A., Fernandez-Guizan A., Acebes-Huerta A., et al. Prognostic significance of CD8 and CD4 T cells in chronic lymphocytic leukemia. Leukemia and Lymphoma 2010, 51:1829-1836.
24. Nunes C., Wong R., Mason M., Fegan C., Man S., Pepper C. Expansion of a CD8(+)PD-1(+) replicative senescence phenotype in early stage CLL patients is associated with inverted CD4:CD8 ratios and disease progression. Clinical Cancer Research 2012, 18:678-687.
25. Tinhofer I., Marschitz I., Kos M., Henn T., Egle A., Villunger A., et al. Differential sensitivity of CD4+ and CD8+ T lymphocytes to the killing efficacy of Fas (Apo-1/CD95) ligand+ tumor cells in B chronic lymphocytic leukemia. Blood 1998, 91:4273-4281.
26. Cantwell M., Hua T., Pappas J., Kipps T.J. Acquired CD40-ligand deficiency in chronic lymphocytic leukemia. Nature Medicine 1997, 3:984-989.
27. Rossi E., Matutes E., Morilla R., Owusu-Ankomah K., Heffernan A.M., Catovsky D. Zeta chain and CD28 are poorly expressed on T lymphocytes from chronic lymphocytic leukemia. Leukemia 1996, 10:494-497.
28. Burger J.A., Tsukada N., Burger M., Zvaifler N.J., Dell'Aquila M., Kipps T.J. Blood-derived nurse-like cells protect chronic lymphocytic leukemia B cells from spontaneous apoptosis through stromal cell-derived factor-1. Blood 2000, 96:2655-2663.
29. Burger J.A., Quiroga M.P., Hartmann E., Burkle A., Wierda W.G., Keating M.J., et al. High-level expression of the T-cell chemokines CCL3 and CCL4 by chronic lymphocytic leukemia B cells in nurselike cell cocultures and after BCR stimulation. Blood 2009, 113:3050-3058.
30. Dal Porto J.M., Gauld S.B., Merrell K.T., Mills D., Pugh-Bernard A.E., Cambier J. B cell antigen receptor signaling 101. Molecular Immunology 2004, 41:599-613.
31. Niiro H., Clark E.A. Regulation of B-cell fate by antigen-receptor signals. Nature Reviews Immunology 2002, 2:945-956.
32. Pierce S.K., Liu W. The tipping points in the initiation of B cell signalling: how small changes make big differences. Nature Reviews Immunology 2010, 10:767-777.
33. Gauld S.B., Dal Porto J.M., Cambier J.C. B cell antigen receptor signaling: roles in cell development and disease. Science 2002, 296:1641-1642.
34. Chiorazzi N., Ferrarini M. B cell chronic lymphocytic leukemia: lessons learned from studies of the B cell antigen receptor. Annual Review of Immunology 2003, 21:841-894.
35. Stevenson F.K., Caligaris-Cappio F. Chronic lymphocytic leukemia: revelations from the B-cell receptor. Blood 2004, 103:4389-4395.
36. Ghiotto F., Fais F., Valetto A., Albesiano E., Hashimoto S., Dono M., et al. Remarkably similar antigen receptors among a subset of patients with chronic lymphocytic leukemia. Journal of Clinical Investigation 2004, 113:1008-1016.
37. Stamatopoulos K., Belessi C., Moreno C., Boudjograh M., Guida G., Smilevska T., et al. Over 20% of patients with chronic lymphocytic leukemia carry stereotyped receptors: Pathogenetic implications and clinical correlations. Blood 2007, 109:259-270.
38. Widhopf G.F., Rassenti L.Z., Toy T.L., Gribben J.G., Wierda W.G., Kipps T.J. Chronic lymphocytic leukemia B cells of more than 1% of patients express virtually identical immunoglobulins. Blood 2004, 104:2499-2504.
39. Stevenson F.K., Krysov S., Davies A.J., Steele A.J., Packham G. B-cell receptor signaling in chronic lymphocytic leukemia. Blood 2011, 118:4313-4320.
40. Stadanlick J.E., Kaileh M., Karnell F.G., Scholz J.L., Miller J.P., Quinn W.J., et al. Tonic B cell antigen receptor signals supply an NF-kappaB substrate for prosurvival BLyS signaling. Nature Immunology 2008, 9:1379-1387.
41. Frank D.A., Mahajan S., Ritz J. B lymphocytes from patients with chronic lymphocytic leukemia contain signal transducer and activator of transcription (STAT) 1 and STAT3 constitutively phosphorylated on serine residues. Journal of Clinical Investigation 1997, 100:3140-3148.
42. Liu Z., Hazan-Halevy I., Harris D.M., Li P., Ferrajoli A., Faderl S., et al. STAT-3 activates NF-kappaB in chronic lymphocytic leukemia cells. Molecular Cancer Research 2011, 9:507-515.
43. Quesada V., Conde L., Villamor N., Ordonez G.R., Jares P., Bassaganyas L., et al. Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia. Nature Genetics 2012, 44:47-52.
44. Wang L., Lawrence M.S., Wan Y., Stojanov P., Sougnez C., Stevenson K., et al. SF3B1 and other novel cancer genes in chronic lymphocytic leukemia. New England Journal of Medicine 2011, 365:2497-2506.
45. Puente X.S., Pinyol M., Quesada V., Conde L., Ordonez G.R., Villamor N., et al. Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia. Nature 2011, 475:101-105.
46. Ishii K.J., Akira S. Innate immune recognition of, and regulation by, DNA. Trends in Immunology 2006, 27:525-532.
47. Iwasaki A., Medzhitov R. Regulation of adaptive immunity by the innate immune system. Science 2010, 327:291-295.
48. Balatti V., Bottoni A., Palamarchuk A., Alder H., Rassenti L.Z., Kipps T.J., et al. NOTCH1 mutations in CLL associated with trisomy 12. Blood 2012, 119:329-331.
49. Screpanti I., Bellavia D., Campese A.F., Frati L., Gulino A. Notch, a unifying target in T-cell acute lymphoblastic leukemia?. Trends in Molecular Medicine 2003, 9:30-35.
50. Khanna K.K., Jackson S.P. DNA double-strand breaks: signaling, repair and the cancer connection. Nature Genetics 2001, 27:247-254.
51. Dohner H., Stilgenbauer S., Benner A., Leupolt E., Krober A., Bullinger L., et al. Genomic aberrations and survival in chronic lymphocytic leukemia. New England Journal of Medicine 2000, 343:1910-1916.
52. Fegan C., Robinson H., Thompson P., Whittaker J.A., White D. Karyotypic evolution in CLL: identification of a new sub-group of patients with deletions of 11q and advanced or progressive disease. Leukemia 1995, 9:2003-2008.
53. Austen B., Skowronska A., Baker C., Powell J.E., Gardiner A., Oscier D., et al. Mutation status of the residual ATM allele is an important determinant of the cellular response to chemotherapy and survival in patients with chronic lymphocytic leukemia containing an 11q deletion. Journal of Clinical Oncology 2007, 25:5448-5457.
54. Guarini A., Marinelli M., Tavolaro S., Bellacchio E., Magliozzi M., Chiaretti S., et al. ATM gene alterations in chronic lymphocytic leukemia patients induce a distinct gene expression profile and predict disease progression. Haematologica 2012, 97:47-55.
55. Ezdinli E.Z., Stutzman L., Aungst C.W., Firat D. Corticosteroid therapy for lymphomas and chronic lymphocytic leukemia. Cancer 1969, 23:900-909.
56. Greenstein S., Ghias K., Krett N.L., Rosen S.T. Mechanisms of glucocorticoid-mediated apoptosis in hematological malignancies. Clinical Cancer Research 2002, 8:1681-1694.
57. Molica S. High-dose dexamethasone in refractory B-cell chronic lymphocytic leukemia patients. American Journal of Hematology 1994, 47:334.
58. Thornton P.D., Matutes E., Bosanquet A.G., Lakhani A.K., Grech H., Ropner J.E., et al. High dose methylprednisolone can induce remissions in CLL patients with p53 abnormalities. Annals of Hematology 2003, 82:759-765.
59. Bellosillo B., Pique M., Barragan M., Castano E., Villamor N., Colomer D., et al. Aspirin and salicylate induce apoptosis and activation of caspases in B-cell chronic lymphocytic leukemia cells. Blood. 1998, 92:1406-1414.
60. Ryan E.P., Pollock S.J., Kaur K., Felgar R.E., Bernstein S.H., Chiorazzi N., et al. Constitutive and activation-inducible cyclooxygenase-2 expression enhances survival of chronic lymphocytic leukemia B cells. Clinical Immunology 2006, 120:76-90.
61. Ryan E.P., Bushnell T.P., Friedman A.E., Rahman I., Phipps R.P. Cyclooxygenase-2 independent effects of cyclooxygenase-2 inhibitors on oxidative stress and intracellular glutathione content in normal and malignant human B-cells. Cancer Immunology, Immunotherapy 2008, 57:347-358.
62. Shanafelt T.D., Rabe K.G., Kay N.E., Zent C.S., Call T.G., Slager S.L., et al. Statin and non-steroidal anti-inflammatory drug use in relation to clinical outcome among patients with Rai stage 0 chronic lymphocytic leukemia. Leukemia and Lymphoma 2010, 51:1233-1240.
63. Robak P., Linke A., Cebula B., Robak T., Smolewski P. Cytotoxic effect of R-etodolac (SDX-101) in combination with purine analogs or monoclonal antibodies on ex vivo B-cell chronic lymphocytic leukemia cells. Leukemia and Lymphoma 2006, 47:2625-2634.
64. Lindhagen E., Nissle S., Leoni L., Elliott G., Chao Q., Larsson R., et al. R-etodolac (SDX-101) and the related indole-pyran analogues SDX-308 and SDX-309 potentiate the antileukemic activity of standard cytotoxic agents in primary chronic lymphocytic leukaemia cells. Cancer Chemotherapy and Pharmacology 2007, 60:545-553.
65. Young Kwang Chae L.X.T., Keating M.J., Estrov Z. Concurrent use of aspirin with the fludarabine, cyclophophamide, rituximab (fcr) regimen improves outcome in patients with relapsed/refractory CLL 2012, American Society of Hematology, Atlanta, Georgia.
66. Filip-Ciubotaru F.M., Manciuc C., Foia L. Statins and endothelial dysfunction. Revista Medico-Chirurgicala a Societatii de Medici si Naturalisti din Iasi 2009, 113:975-983.
67. Larose E., Ganz P. Statins and endothelial dysfunction. Seminars in Vascular Medicine 2004, 4:333-346.
68. Weitz-Schmidt G. Statins as anti-inflammatory agents. Trends in Pharmacological Sciences 2002, 23:482-486.
69. Davignon J. Beneficial cardiovascular pleiotropic effects of statins. Circulation 2004, 109:III39-III43.
70. Hernandez-Perera O., Perez-Sala D., Navarro-Antolin J., Sanchez-Pascuala R., Hernandez G., Diaz C., et al. Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells. Journal of Clinical Investigation 1998, 101:2711-2719.
71. Wassmann S., Laufs U., Muller K., Konkol C., Ahlbory K., Baumer A.T., et al. Cellular antioxidant effects of atorvastatin in vitro and in vivo. Arteriosclerosis, Thrombosis, and Vascular Biology 2002, 22:300-305.
72. Zhou M.S., Schuman I.H., Jaimes E.A., Raij L. Renoprotection by statins is linked to a decrease in renal oxidative stress, TGF-beta, and fibronectin with concomitant increase in nitric oxide bioavailability. Renal Physiology. American Journal of Physiology 2008, 295:F53-F59.
73. Chapman-Shimshoni D., Yuklea M., Radnay J., Shapiro H., Lishner M. Simvastatin induces apoptosis of B-CLL cells by activation of mitochondrial caspase 9. Experimental Hematology 2003, 31:779-783.
74. Schramm R., Menger M.D., Harder Y., Schmits R., Adam O., Weitz-Schmidt G., et al. Statins inhibit lymphocyte homing to peripheral lymph nodes. Immunology 2007, 120:315-324.
75. Ulivieri C., Fanigliulo D., Benati D., Pasini F.L., Baldari C.T. Simvastatin impairs humoral and cell-mediated immunity in mice by inhibiting lymphocyte homing, T-cell activation and antigen cross-presentation. European Journal of Immunology 2008, 38:2832-2844.
76. Winiarska M., Bil J., Wilczek E., Wilczynski G.M., Lekka M., Engelberts P.J., et al. Statins impair antitumor effects of rituximab by inducing conformational changes of CD20. PLoS Medicine 2008, 5:e64.
77. Friedman D.R., Magura L.A., Warren H.A., Harrison J.D., Diehl L.F., Weinberg J.B. Statin use and need for therapy in chronic lymphocytic leukemia. Leukemia and Lymphoma 2010, 51:2295-2298.
78. Wiestner A. Emerging role of kinase-targeted strategies in chronic lymphocytic leukemia. Blood 2012, 120:4684-4691.
79. Hantschel O., Rix U., Schmidt U., Burckstummer T., Kneidinger M., Schutze G., et al. The Btk tyrosine kinase is a major target of the Bcr-Abl inhibitor dasatinib. Proceedings of the National Academy of Sciences of the United States of America 2007, 104:13283-13288.
80. Amrein P.C., Attar E.C., Takvorian T., Hochberg E.P., Ballen K.K., Leahy K.M., et al. Phase II study of dasatinib in relapsed or refractory chronic lymphocytic leukemia. Clinical Cancer Research 2011, 17:2977-2986.
81. Futosi K., Nemeth T., Pick R., Vantus T., Walzog B., Mocsai A. Dasatinib inhibits proinflammatory functions of mature human neutrophils. Blood 2012, 119:4981-4991.
82. Weinblatt M.E., Kavanaugh A., Genovese M.C., Musser T.K., Grossbard E.B., Magilavy D.B. An oral spleen tyrosine kinase (Syk) inhibitor for rheumatoid arthritis. New England Journal of Medicine 2010, 363:1303-1312.
83. Friedberg J.W., Sharman J., Sweetenham J., Johnston P.B., Vose J.M., Lacasce A., et al. Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. Blood 2010, 115:2578-2585.
84. Cheson B.D., Byrd J.C., Rai K.R., Kay N.E., O'Brien S.M., Flinn I.W., et al. Novel targeted agents and the need to refine clinical end points in chronic lymphocytic leukemia. Journal of Clinical Oncology 2012, 30:2820-2822.
85. Herman S.E., Johnson A.J. Molecular pathways: targeting phosphoinositide 3-kinase p110-delta in chronic lymphocytic leukemia. Clinical Cancer Research 2012, 18:4013-4018.
86. Byrd J.C., Furman R.R., Coutre S.E., Flinn I.W., Burger J.A., Blum K.A., et al. Targeting BTK with Ibrutinib in relapsed chronic lymphocytic leukemia. England Journal of Medicine 2013.
87. Herman S.E., Gordon A.L., Hertlein E., Ramanunni A., Zhang X., Jaglowski S., et al. Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765. Blood 2011, 117:6287-6296.
88. Byrd J.C., Furman R.R., Steven Coutre, Flinn I.W., Burger J.A., Blum K.A., Sharman J.P., Barbara Grant, Jones J.A., Wierda W.G., Weiqiang Zhao, Heerema N.A., Johnson A.J., Anh Tran, Fong Clow, Lori Kunkel, James D.F., Susan O'Brien The Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib (PCI-32765) Promotes High Response Rate, Durable Remissions, and Is Tolerable in Treatment Naïve (TN) and Relapsed or Refractory (RR) Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) Patients Including Patients with High-Risk (HR) Disease: New and Updated Results of 116 Patients in a Phase Ib/II Study 2012, American Society of Hematology, Atlanta, GA.
89. Ponader S., Chen S.S., Buggy J.J., Balakrishnan K., Gandhi V., Wierda W.G., et al. The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo. Blood 2012, 119:1182-1189.
90. Rajkumar S.V., Rosinol L., Hussein M., Catalano J., Jedrzejczak W., Lucy L., et al. Multicenter, randomized, double-blind, placebo-controlled study of thalidomide plus dexamethasone compared with dexamethasone as initial therapy for newly diagnosed multiple myeloma. Journal of Clinical Oncology 2008, 26:2171-2177.
91. Singhal S., Mehta J., Desikan R., Ayers D., Roberson P., Eddlemon P., et al. Antitumor activity of thalidomide in refractory multiple myeloma. New England Journal of Medicine 1999, 341:1565-1571.
92. Carballido E., Veliz M., Komrokji R., Pinilla-Ibarz J. Immunomodulatory drugs and active immunotherapy for chronic lymphocytic leukemia. Cancer Control 2012, 19:54-67.
93. Sampaio E.P., Sarno E.N., Galilly R., Cohn Z.A., Kaplan G. Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes. Journal of Experimental Medicine 1991, 173:699-703.
94. Sheskin J. Thalidomide in the treatment of lepra reactions. Clinical Pharmacology and Therapeutics 1965, 6:303-306.
95. Corral L.G., Haslett P.A., Muller G.W., Chen R., Wong L.M., Ocampo C.J., et al. Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha. Journal of Immunology 1999, 163:380-386.
96. Ramsay A.G., Johnson A.J., Lee A.M., Gorgun G., Le Dieu R., Blum W., et al. Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug. Journal of Clinical Investigation 2008, 118:2427-2437.
97. Badoux X.C., Keating M.J., Wen S., Lee B.N., Sivina M., Reuben J., et al. Lenalidomide as initial therapy of elderly patients with chronic lymphocytic leukemia. Blood 2011, 118:3489-3498.
98. Chanan-Khan A., Miller K.C., Musial L., Lawrence D., Padmanabhan S., Takeshita K., et al. Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study. Journal of Clinical Oncology 2006, 24:5343-5349.
99. Chen C.I., Bergsagel P.L., Paul H., Xu W., Lau A., Dave N., et al. Single-agent lenalidomide in the treatment of previously untreated chronic lymphocytic leukemia. Journal of Clinical Oncology 2011, 29:1175-1181.
100. Ferrajoli A., Lee B.N., Schlette E.J., O'Brien S.M., Gao H., Wen S., et al. Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia. Blood 2008, 111:5291-5297.
101. Chanan-Khan A.A., Cheson B.D. Lenalidomide for the treatment of B-cell malignancies. Journal of Clinical Oncology 2008, 26:1544-1552.
102. Jenny N.S. Inflammation in aging: cause, effect, or both?. Discovery Medicine 2012, 13:451-460.
103. Ivanenkov Y.A., Balakin K.V., Tkachenko S.E. New approaches to the treatment of inflammatory disease: focus on small-molecule inhibitors of signal transduction pathways. Drugs in R&D 2008, 9:397-434.
104. Vijayakrishnan L., Venkataramanan R., Gulati P. Treating inflammation with the Janus kinase inhibitor CP-690,550. Trends in Pharmacological Sciences 2011, 32:25-34.
105. Martinez-Lostao L., Briones J., Forne I., Martinez-Gallo M., Ferrer B., Sierra J., et al. Role of the STAT1 pathway in apoptosis induced by fludarabine and JAK kinase inhibitors in B-cell chronic lymphocytic leukemia. Leukemia and Lymphoma 2005, 46:435-442.
106. Furman R.R., Byrd J.C., Brown J.R., Coutre S.E., Benson D.M., Wagner-Johnston N.D., et al. CAL-101, An Isoform-Selective Inhibitor of Phosphatidylinositol 3-Kinase P110 delta, Demonstrates Clinical Activity and Pharmacodynamic Effects In patients with Relapsed or Refractory Chronic Lymphocytic Leukemia. Blood 2010, 116. 31.